Janice Weinberg

Janice Weinberg

Auto-generated profile, based on publicly available information

Janice Weinberg

School of Public Health, Boston University, Boston, USA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2008 in Environmental Health
Verified
Journal Article
Open access
PDF file
EHElizabeth E Hatch
Elizabeth E Hatch
JNJessica W Nelson
Jessica W Nelson
MQM Mustafa Qureshi
M Mustafa Qureshi
JWJanice Weinberg
Janice Weinberg
LMLynn Moore
Lynn Moore
TWThomas Webster
Thomas Webster
Although diet and activity are key factors in the obesity epidemic, laboratory studies suggest that endocrine disrupting chemicals may also affect obesity.

1 March 2013 in Environmental Health Perspectives
Verified
Journal Article
Open access
VVVeronica Vieira
Veronica Vieira
KHKate Hoffman
Kate Hoffman
Hyeong-Moo ShinHyeong-Moo Shin
Hyeong-Moo Shin
JWJanice M. Weinberg
Janice M. Weinberg
TWThomas Webster
Thomas Webster
TFTony Fletcher
Tony Fletcher
A peer-reviewed open access journal published by the National Institute of Environmental Health Sciences

22 June 2015 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
LRLisa M. Rice
Lisa M. Rice
CPCristina M. Padilla
Cristina M. Padilla
SMSarah R. McLaughlin
Sarah R. McLaughlin
AMAllison Mathes
Allison Mathes
JZJessica Ziemek
Jessica Ziemek
RLRobert Lafyatis
Robert Lafyatis
BACKGROUND. TGF-β has potent profibrotic activity in vitro and has long been implicated in systemic sclerosis (SSc), as expression of TGF-β–regulated genes is increased in the skin and lungs of patients with SSc. Therefore, inhibition of TGF-β may benefit these patients. METHODS. Patients with early, diffuse cutaneous SSc were enrolled in an open-label trial of fresolimumab, a high-affinity neutralizing antibody that targets all 3 TGF-β isoforms. Seven patients received two 1 mg/kg doses of fresolimumab, and eight patients received one 5 mg/kg dose of fresolimumab. Serial mid-forearm skin biopsies, performed before and after treatment, were analyzed for expression of the TGF-β–regulated biomarker genes thrombospondin-1 (THBS1) and cartilage oligomeric protein (COMP) and stained for myofibroblasts. Clinical skin disease was assessed using the modified Rodnan skin score (MRSS). RESULTS. In patient skin, THBS1 expression rapidly declined after fresolimumab treatment in both groups (P = 0.0313 at 7 weeks and P = 0.0156 at 3 weeks), and skin expression of COMP exhibited a strong downward trend in both groups. Clinical skin disease dramatically and rapidly decreased (P < 0.001 at all time points). Expression levels of other TGF-β–regulated genes, including SERPINE1 and CTGF, declined (P = 0.049 and P = 0.012, respectively), and a 2-gene, longitudinal pharmacodynamic biomarker of SSc skin disease decreased after fresolimumab treatment (P = 0.0067). Dermal myofibroblast infiltration also declined in patient skin after fresolimumab (P < 0.05). Baseline levels of THBS1 were predictive of reduced THBS1 expression and improved MRSS after fresolimumab treatment. CONCLUSION. The rapid inhibition of TGF-β–regulated gene expression in response to fresolimumab strongly implicates TGF-β in the pathogenesis of fibrosis in SSc. Parallel improvement in the MRSS indicates that fresolimumab rapidly reverses markers of skin fibrosis. TRIAL REGISTRATION. Clinicaltrials.gov NCT01284322. FUNDING. This study was supported by the Boston University Clinical and Translational Science Institute, the NIH’s National Center for Advancing Translational Sciences Clinical and Translational Sciences, the National Institute of Arthritis Musculoskeletal and Skin Disease: Scleroderma Core Centers and Scleroderma Center of Research Translation, the Boston University Medical Campus Microarray Core, the Kellen Foundation at Hospital for Special Surgery, the Scleroderma Research Foundation, the Dr. Ralph and Marian Falk Medical Research Trust, and Novartis.

8 January 2007 in Journal of the American Geriatrics Society
Verified
Journal Article
Closed access
PDF file
KBKerry E. Broe
Kerry E. Broe
TCTai Cheng Chen
Tai Cheng Chen
JWJanice Weinberg
Janice Weinberg
HBHeike A. Bischoff‐Ferrari
Heike A. Bischoff‐Ferrari
Michael HolickMichael Holick
Michael Holick
DKDouglas P Kiel
Douglas P Kiel

1 April 2007 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
BPBruce A. Perkins
Bruce A. Perkins
LFLinda Ficociello
Linda Ficociello
BOBetsy E. Ostrander
Betsy E. Ostrander
KSKristen H. Silva
Kristen H. Silva
JWJanice Weinberg
Janice Weinberg
AKAndrzej S. Krolewski
Andrzej S. Krolewski
This study aimed to establish the time of initiation and the determinants of renal function decline in type 1 diabetes. Until now, such decline has been assumed to be a late-occurring event associated with proteinuria. A total of 267 patients with normoalbuminuria and 301 patients with microalbuminuria were followed for 8 to 12 yr. Linear trends (slopes) in GFR were estimated by serial measurement of serum cystatin C. Cases of early renal function decline were defined by loss in cystatin C GFR that exceeded −3.3%/yr, a threshold that corresponds to the 2.5th percentile of the distribution of GFR slopes in an independent nondiabetic normotensive population. Cases of early renal function decline occurred in 9% (mean slope −4.4; range −5.9 to −3.3%/yr) of the normoalbuminuria group and 31% (mean slope −7.1; range −23.8 to −3.3%/yr) of the microalbuminuria group (P < 0.001). Risk for early renal function decline depended on whether microalbuminuria regressed, remained stable, or progressed, rising from 16 to 32 and 68%, respectively (P < 0.001). In multivariate analysis, risk for decline was higher after age 35 yr or when glycosylated hemoglobin exceeded 9% but did not vary with diabetes duration, smoking, BP, or angiotensin-converting enzyme inhibitor treatment. Contrary to the existing paradigm of diabetic nephropathy, progressive renal function decline in type 1 diabetes is an early event that occurs in a large proportion of patients with microalbuminuria. Together with testing for microalbuminuria, clinical protocols using cystatin C to diagnose early renal function decline and track response to therapeutic interventions should be developed.

1 December 2010 in Environmental Health Perspectives
Verified
Journal Article
Open access
KHKate Hoffman
Kate Hoffman
TWThomas Webster
Thomas Webster
MWMarc G. Weisskopf
Marc G. Weisskopf
JWJanice Weinberg
Janice Weinberg
VVVerónica M. Vieira
Verónica M. Vieira
A peer-reviewed open access journal published by the National Institute of Environmental Health Sciences